Press Release FeedGet the RSS feed
Menu

Business Wire

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire

RAMP 201 study supported FDA Accelerated Approval of AVMAPKI FAKZYNJA CO-PACK for treatment of KRAS-mutated recurrent LGSOC following prior systemic therapy

Across patients with KRAS wild-type and KRAS-mutated recurrent LGSOC, the combination had a median duration of response of 31.1 months, median progression free survival of 12.9 months, and a safety profile consistent with the primary analysis

BOSTON, September 28, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Gynecologic Oncology, the official journal of the Society of Gynecologic Oncology (SGO), has published two-year long-term results from the Phase 2 RAMP 201 study evaluating AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in women with recurrent low-grade serous ovarian cancer (LGSOC). The manuscript, titled "Long-Term Efficacy and Safety of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Results of a 2-Year Follow Up of ENGOT-OV60/GOG-3052/RAMP 201​" has been published online and will appear in the October 2026 print issue of Gynecologic Oncology.

"Data published in this analysis of RAMP 201 accounts for more than two years of follow-up, further reinforcing the clinically meaningful and durable activity observed with the combination of avutometinib and defactinib in recurrent low-grade serous ovarian cancer," said Professor Susana Banerjee, M.B.B.S., M.A., Ph.D., F.R.C.P, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and Team Leader in Women's Cancers at The Institute of Cancer Research, London and Global Lead Principal Investigator of ENGOTov60/GOG3052/NCRI/RAMP201. "These results strengthen our confidence in the consistency of response and disease control seen across patients and highlight the important role this combination treatment should play for this rare ovarian cancer."

"Low-grade serous ovarian cancer is a rare and distinct form of ovarian cancer with a unique biology and clinical behavior different from other ovarian cancers. Patients with this disease often experience delays in diagnosis and have historically had limited treatment options," said John Hayslip, M.D., chief medical officer at Verastem Oncology. "Data from this longer-term analysis, also presented during a scientific plenary session at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers, further underscore the durable responses, safety, and tolerability of avutometinib in combination with defactinib across patients with KRAS wild-type or KRAS-mutated LGSOC."

  1. SaaSThe Prostate Cancer FoundationProstate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types – – New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges i
  2. FinanceAlign Technology, Inc.Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent CourtCompanies: Align TechnologySAN JOSE, Calif. & TEMPE, Ariz., October 17, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, welcomes the decision of the Unified Patent Court ("UPC") finding that aligner syst
  3. AISyncra and Neumetry Partner to Build AI-Powered Readiness Platform for Teenage Athletes and Their CoachesSmart ring data meets FDA-cleared physiological AI to help coaches see which athletes are ready to compete, and which need rest LAS VEGAS & SAN JOSE, Calif., October 17, 2026--Syncra Labs Inc., maker of the Syncra smart ring, and Neumetry Medical, Inc., developer of an FDA-cleared predictive health pla
  4. HealthcareAIDS Healthcare FoundationAHF Commemorates 40 Years of Global Impact During Annual World AIDS Day Concert Celebration Featuring Ricky MartinLOS ANGELES, October 16, 2026--AIDS Healthcare Foundation (AHF) , the world's largest, non-profit public health organization providing direct HIV/ADS services to over 3.3 million clients across the globe, will celebrate 40 years of impact during its annual World AIDS Day concert commemoration. Continu
  5. Real estateKBRA Assigns Preliminary Ratings to Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6)NEW YORK, October 16, 2026--KBRA assigns preliminary ratings to ten classes of mortgage-backed certificates from Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6), a $250.6 million non-prime RMBS transaction. The underlying collateral, comprised of 381 residential mortgages, and includes a meaningful conce
  6. FinanceUL SolutionsUL Solutions Warns of GFCI and Duplex Wall Outlets Modified by Third Parties to Include Built-in CamerasAfter manufacturing, third parties added built-in cameras to the wall outlets; UL Solutions did not evaluate the modified products and recommends that they be immediately removed from service and discarded. NORTHBROOK, Ill., October 16, 2026--UL Solutions (NYSE: ULS), a global leader in applied safety